SCHEMBL4672893

SCHEMBL4672893

O=C(C=C(O)c1nc[nH]n1)c1ccc(Cc2ccc(O)cc2)o1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.34
HSD17B10 Q99714 1/20 0.34
HTT P42858 1/20 0.33
THRA P10827 1/20 0.33
THRB P10828 1/20 0.33
POLB P06746 5/20 0.32
TDP1 Q9NUW8 2/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
MAPT P10636 2/20 0.32
PTGER1 P34995 1/20 0.32
NPC1 O15118 3/20 0.32
RAB9A P51151 3/20 0.32
ALDH1A1 P00352 2/20 0.32
GAA P10253 1/20 0.32
MRGPRX4 Q96LA9 1/20 0.32
KMT2A Q03164 2/20 0.32
MAPK1 P28482 1/20 0.32
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
CYP1A2 P05177 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4678961 0.92 PTGER1 (0.36) SMN1; SMN2HSD17B10HTTPOLBTDP1
SCHEMBL4678600 0.91 HSD17B10 (0.41) SMN1; SMN2HSD17B10HTTPOLBMAPT
SCHEMBL4676637 0.90 ELANE (0.33) SMN1; SMN2HSD17B10HTTTDP1ALDH1A1
S-1360 SCHEMBL3221454 0.90 CYP1A2 (0.36) SMN1; SMN2HTTPOLBTDP1L3MBTL1
SCHEMBL4672873 0.90 ALDH1A1 (0.41) SMN1; SMN2HTTPOLBTDP1MAPT
S-1360 SCHEMBL10070153 0.90 CYP1A2 (0.36) SMN1; SMN2HTTPOLBTDP1L3MBTL1
SCHEMBL4671675 0.90 LMNA (0.34) SMN1; SMN2HSD17B10HTTPOLBMAPT
S-1360 SCHEMBL6853679 0.89 CYP1A2 (0.35) SMN1; SMN2HTTPOLBTDP1L3MBTL1
SCHEMBL4675956 0.88 KMT2A (0.38) SMN1; SMN2HTTPOLBL3MBTL1MAPT
SCHEMBL4675232 0.88 ALDH1A1 (0.44) HTTPOLBTDP1L3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 SMN1; SMN2 4107/4885HSD17B10 241/4885HTT 1204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.